As vascular calcification in patients with kidney disease is no longer seen as a passive process resulting from an elevated calcium-phosphate product [98], vitamin D receptor agonist therapy seems to play a decisive role in contrasting vascular calcification, a dire complication of CKD closely associated with cardiovascular mortality [99]. This evidence concerns the gene VDR and chronic kidney disease.